1 The debrisoquine hydroxylase (CYP2D6) is polymorphically distributed. Not only are there differences in the proportions of extensive metabolisers to poor metabolisers in various ethnic groups, but there are also pronounced variations in the metabolic capacity among those classified as extensive metabolisers. 2 The mean debrisoquine metabolic ratio of Caucasian extensive metabolisers is lower than that for a number of African populations. In the present study, we have searched for novel CY P2D6 mutations to explain the diminished enzyme activity in African populations. 3 Three Zimbabwean Shona subjects with EM phenotypes (metabolic ratios for debrisoquine of 0.4, 1.5 and 10.5 respectively) were selected and the open reading frame of the CY P2D6 gene of each was sequenced. 4 The subject with metabolic ratio of 10.5 was found to be homozygous for an allele with a nucleotide exchange in exon 2, 1111C T causing a 107Thr Ile amino acid exchange in a conserved region of the enzyme. In addition, he was homozygous for the 2938C T and 4268G C mutations causing 296Arg Ser and 486Ser Thr amino acid substitution found in the CY P2D6*2 allele. 5 Seventy-six Zimbabwean Shona subjects were subsequently genotyped for the 1111C T mutation and for the intron 1 gene conversion present in the CY P2D6*2 gene. The 1111C T mutation was found at an allele frequency of 34% and was only present in alleles carrying the gene conversion in intron 1 indicative for the CY P2D6*2 gene. 6 This allele (CY P2D6*17), containing the 1111C T, 2938C T and 4268G C mutations, was found to be strongly associated with lower capacity for debrisoquine hydroxylation. We therefore postulate that the CY P2D6*17 allele might contribute to the molecular basis of the previously established diminished debrisoquine hydroxylase activity in African Bantu populations.
Keywords African population Bantu Zimbabwe drug metabolism debrisoquine genetic polymorphism interethnic differences Introduction Analysis of the number of genes in the locus, and the genotype for CYP2D6*3, *4, *9 and *10 alleles in these subjects were performed in the previous study [ 6] with The genetic polymorphism of debrisoquine hydroxylase (CYP2D6) has been a subject of great interest, methods described [19] [20] [21] . particularly as the enzyme metabolises over 40 clinically important drugs [1, 2 ] . Clinical implications of the poor metaboliser (PM) vs the extensive metaboliser Materials (EM) phenotypes have been investigated and these studies showed that PM subjects experience side effects Heat stable DNA polymerase was purchased from Advanced Biotechnologies, London, UK and PCRs at normal doses of drugs that are substrates of CYP2D6 [ 2] . Using debrisoquine as a probe drug, the were performed on a Perkin Elmer Thermocycler 480. Sequenase version 2.0 T7 DNA polymerase and the prevalence of PMs is 0-1% in Orientals (Chinese, Koreans and Japanese) [3 ] , 5-10% in Caucasians Sequenase kit used were from United States Biochemicals. Allele specific primers were obtained from (Europeans) [4 ] and 0-5% in some black African populations [ 5, 6 ] . The molecular genetic basis for the KEBO (Sweden). All chemicals used were of highest available quality. poor metaboliser status in various populations has been shown to be the homozygous occurrence of any of a number of defective alleles, the most common being the CYP2D6*3 (frame shift mutation), CYP2D6*4 CYP2D6 gene sequencing (splice mutation) CYP2D6*5 (gene deletion) and CY P2D6*6 (frame shift) [7] [8] [9] [10] [11] .
CYP2D6 specific primers were used to amplify segments of the gene and single strands were generated by using Attention has now also been directed to the EM category since within this group there is a variation in biotinylated primers and streptavidin (Dynal) separation, or assymmetric PCR. at 72°C. Magnesium concentrations were titrated for the different primers for optimal (specific) amplifiblack Africans [6, 10, 14] . The molecular basis of the enhanced metabolic capacity was found to be gene cations. Assymmetric PCR was performed under the same conditions as above with minor modifications, duplication or gene amplification of the CYP2D6*2 allele and subjects with up to 13 functional copies have 5 ml of the first PCR and an excess of one of the primers flanking the exon of interest was used. Shorter been described [15] [16] [17] .
In a previous study on a Zimbabwean Shona annealing and elongation times of 30 s were used and only 25 cycles were run. The PCR products were population, as well as in retrospective analysis of phenotyping studies done in other black African popuanalysed on agarose gel and single stranded DNA (ssDNA) was visible as a band additional to the lations, a general tendency towards higher metabolic ratios for CYP2D6 probe drugs can be noted [6 ] . The original one. The ssDNA was precipitated and then dissolved in water, ready for sequencing. Where low frequency in the Zimbabwean population of the CY P2D6*10 variant and the lack of the CYP2D6*9 biotinylated primers were used, streptavidin coated magnetic beads (Dynal) and alkaline denaturation was allele, both of which encode an enzyme with low debrisoquine hydroxylase activity in Orientals and used to separate the strands from the first PCR reaction. The non-biotinylated strand was also used for Caucasians, respectively [18] [19] [20] , showed that these alleles could not account for the shift to higher metabolic sequencing after neutralisation with HCl. Table 1 shows the primers used for the amplification of CY P2D6 ratios in the black Bantu population. Thus, in order to establish the genetic basis for the diminished CYP2D6 exons and for sequencing. Sequencing was performed by the double-stranded dideoxynucleotide chainactivity among EMs in the Zimbabwean population, we have investigated the CYP2D6 sequence in several termination method on all exons from both directions, covering the intron-exon junctions. individuals with known phenotypes.
PCR-based allele-specific analysis Methods
Genotyping for the exon 2 1111C T mutation From sequence analysis, a mutation (1111C T) was identified DNA samples in exon 2 of an extensive metaboliser with a high debrisoquine metabolic ratio. A PCR-based genotyping DNA was isolated from 76 subjects who participated in our previous CYP2D6 phenotyping and genotyping assay for this mutation was developed so that all 76 DNA samples could be assessed for the mutation. studies on a Zimbabwean Shona population [6 ] . Table 1 Primers for PCR and sequencing of CYP2D6 exons 1-9, and allele specific PCR for CYP2D6*17
Primers for amplification
Primers for sequencing Site Name Sequence Exon Name Sequence
Pr ex4F 5∞-GATGGGCAGAAGGGCAC-3∞(F) Pr 2 5∞GAGACTCCTCGGTCTC-3∞(R) Exon 5+6
Pr ex5FB 5∞-GCCTGAGACTTGTCCAGG-3∞ ( Exon 1 and 2 were amplified from genomic DNA using Data analysis CY P2D6 specific primers Pr9B and Prex2R (Table 1) . Thirty-five cycles were run with annealing temperature Multiple comparison of the genotype groups (wt/wt, wt/*2, wt/*17 and *17/*17) was performed using the at 60°C and 0.8 m magnesium chloride was used in the incubations. A second allele-specific set of PCRs Kruskal-Wallis test (ANOVA by Ranks). For comparisons between the individual groups the Mann-Whitney was run on the product of the first PCR (Figure 2 ) for 15 cycles at 60°C annealing temperature and 0.6 m U-test was used. Metabolic ratios used were those determined in the previous study [ 6] . magnesium chloride. All PCR products were analysed on 1.5% agarose gels stained with ethidium bromide.
Genotyping for the CYP2D6*2 variant From sequence analysis, the exon 2 mutation was also associated with Results the mutations in exon 3, 6 and 9 found in the CYP2D6*2 allele. Previously, Johansson et al. [15 ] have shown All nine exons of CYP2D6 in DNA from three subjects, Z69 (metabolic ratio, 0.4), Z5 (metabolic ratio, 1.5), and that the CY P2D6*2 variant always is associated with a mutation in intron 1 (a gene conversion event from Z38 (metabolic ratio, 10.5) were sequenced. No nucleotide differences were found in the sequences of exons 1, pseudogene CY P2D7), and that the genotype of the former can be established by analysis of the latter. To 4, 5, 7, and 8 compared with the wild type published sequence [ 22] . Table 2 shows the mutations found in identify the CY P2D6 genotype with respect to the CY P2D6*2-variant we therefore analysed the intron 1 exons 2, 3, 6 and 9. A novel mutation was found in exon 2 of DNA from Z5 and Z38, whereas the other sequence. A primer in the pre-exon 1 sequence (Pr 9B) and a primer in the intron 1 sequence (either one with mutations in exons 3, 6, and 9 are those characteristic of the CYP2D6*2 allele. Figure 1 shows sequencing the wild type sequence, Pr 10, or the one, Pr 10B, specific for the sequence between bp302 and 333 in results for Z69 and Z38 illustrating the C T mutation found at base pair 1111 in exon 2 of Z38 with the wild intron 1, which is identical to the converted sequence from pseudogene CYP2D7P ), were used for alleletype sequence exhibited by Z69. This allele, thus containing the 1111C T, 1726G C, 2938C T and specific amplification [ 15]. All the other exons had sequences identical to those reported for the wildtype allele [22] .
post-test for comparisons between the individual groups, it is evident that the CYP2D6*2 allele does not significantly influence the enzyme activity, whereas the CYP2D6*17 allele, is strongly associated with metabolic ratios that are higher than those of the wild-type and CYP2D6*2 allele combinations (Table 3 ). Figure 3 shows the frequency distribution of debrisoquine metabolic ratios for 59 subjects classified as extensive metabolisers in a previous study [ 6] . In this figure, only subjects of XbaI 29/29 kb haplotype (without CYP2D6*3, *4, *5, *9 and *10 mutations or other known XbaI haplotype variants) were included so as to illustrate the relationship of the CYP2D6*17 allele with the MR for debrisoquine. The subjects with the CYP2D6*2 allele were included in the wild type group since it is apparent from Table 3 and the findings of allele and those with one or two alleles bearing Genotyping of all 76 DNA samples was performed mutations associated with decreased CYP2D6 activity for the exon 2 (1111C T) mutation and the CYP2D6*2 had higher MRs than those with two functional alleles. variant by the intron 1 analysis method [15 ] . Figure 2 Three individuals with the *17 allele were also omitted shows results of the allele specific PCR amplification because they carried other mutations in addition, two assay developed for the exon 2 mutation. All subjects with *10 and one with the XbaI 42 kb RFLP. carrying this mutation also had the CYP2D6*2 variant sequence in intron 1 derived from CY P2D7P by gene conversion into the CYP2D6 gene. This strongly indicates that all these subjects are carriers of the CY P2D6*17 allele. The allele frequency of the exon 2 Discussion mutation was 34% and the allele frequency of the intron 1 gene conversion was 47%, indicating that 13%
We report here on a mutant variant of the CY P2D6 gene in a black African population termed CYP2D6*17. of the subjects analysed carried the CYP2D6*2 allele. From the observed CYP2D6*17 allele frequency of 0.34, This allele contains a 1111C T mutation in exon 2, together with the previously characterised mutations in the expected genotype frequencies using the HardyWeinberg equation for prediction of allele frequencies exon 3, 6, and 9 and the gene conversion in intron 1 which are characteristics of CYP2D6*2. In the popuin a population, for wt/wt, wt/mt and mt/mt are 0.44, 0.45 and 0.12. These values are similiar to the observed lation studied, the CYP2D6*2 allele does occur without the CYP2D6*17 exon 2 mutation, whereas the opposite values of 0.49, 0.35 and 0.16 respectively. Table 3 shows the median debrisoquine MR among combination was not found. The CYP2D6*17 allele was present at a very high frequency of 34% and obeys the subjects carrying the CY P2D6*2 or the CYP2D6*17 alleles. A significant difference between the MRs in the Hardy-Weinberg principle predicting the frequency distribution of a mutant allele in a population. genotype groups was found with the Kruskal-Wallis test (P<0.0001). Using the Mann-Whitney U test as
Since previously described defective alleles, such as a b Figure 2 (a) A schematic diagram of the strategy used for allele specific genotyping of the 1111C T mutation of the CY P2D6*17 allele. A gene specific fragment of 1417 bp was first amplified by PCR and the 1111C T mutation was evaluated in a second PCR step using mutation specific and wild type specific primers. (b) Agarose gel separation of the PCR amplification products obtained in the first (top) and the second PCR steps (bottom). CY P2D6*3, *4, *5, *9 and *10, occur at a very low Ethiopians, a non-Bantu African population, at an allele frequency of 10% and associated with diminished frequency in the Zimbabwean Shona population [6 ] , their contribution to the general shift towards higher enzyme activity [ 24] . It is conceivable that the molecular basis for diminished CYP2D6 enzyme activity in Bantu debrisoquine MRs in the population is minor. Our results indicate a convincing association of the populations is the high frequency of occurrence of the CYP2D6*17 allele. CY P2D6*17 allele with high debrisoquine metabolic ratios (diminished enzyme activity) of extensive metabThe 1111C T mutation in exon 2 causes an amino acid change from the hydrophilic 107Thr to the hydroolisers. The Zimbabwean Shona population belongs to the Bantu people (black Africans populating the region phobic Ile. This change takes place in a region (b∞-helix) which is shown to be conserved in alignment studies from Cameroon to Central and Eastern Africa, and most of Southern Africa) who are genetically closely between CYP2D6 and CYP101 [25 ] . This amino acid change may therefore disturb the structure of CYP2D6. related [ 23] . We have examined the CYP2D6*17 prevalence in some Oriental (Chinese) and Caucasian
The 107Thr is located in a region corresponding to a putative substrate-recognition site (SRS1) in Gotoh's (Swedish) subjects where it was absent (Oscarsson et al., unpublished data). We have, however, found it among model of six SRSs for the CYP2 family [26 ] . Amino
